Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca has entered into an exclusive global licence agreement, excluding Greater China, with Jacobio Pharmaceuticals for JAB-23E73, a potential…
Fierce Pharma Asia: AstraZeneca's KRAS bet; BeiGene's cancer deal; Coherus' PD-1 price. The article discusses AstraZeneca's $2B Jacobio pan-KRAS commitment…
Jacobio Pharma announced it has received the US$100 million upfront payment from AstraZeneca under the JAB-23E73 collaboration and license agreement announced…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
AstraZeneca licensed exclusive ex-China rights to Jacobio's JAB-23E73, a Phase 1 pan-KRAS inhibitor (oral small molecule sparing HRAS/NRAS), announced December 21, 2025. Jacobio receives $100M upfront and up to $1.915B in development/commercial milestones plus tiered royalties; Jacobio retains co-development/commercialization rights in China (total up to ~$2.015B). The agreement became effective with Jacobio confirming receipt of the $100M upfront on March 30, 2026. JAB-23E73 has produced the first clinical data for a pan-KRAS inhibitor: in the China Phase 1a dose-escalation (42 patients as of Jan 15, 2026) multiple confirmed partial responses were seen, with a 38.5% ORR and 84.6% DCR among 13 pancreatic-cancer patients in the efficacious dose range and Grade 3 TRAEs of 11.9% (no Grade 4/5). China's CDE approved a Phase 1/3 first-line KRAS-mutant pancreatic combination (nab-paclitaxel + gemcitabine) in February 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. (this deal) | 2025 | $2.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Oncology deals